Lexeo Therapeutics Announces Interim Data From Its Ongoing HEROIC-PKP2 Phase I/II Clinical Trial Of LX2020 For Treatment Of PKP2 Arrhythmogenic Cardiomyopathy; Across Ten Participants, Including Nine With At Least 12 Months Of Follow-up, Treatment With...